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Abstract—The increase of obesity, its related diseases and 
the high incidence of metabolic diseases as a whole, constitute a 
major public health problem on a global scale. New strategies 
that allow for the discovery of novel metabolic disease-related 
genes are necessary to develop new treatments. In this paper, we 
proposed an efficient method to predict metabolic disease genes, 
solving the problem of imbalanced data. The method combined 
protein-protein interactions and miRNA-target interactions to 
construct integrated networks, whose topological properties can 
be used as features to train machine learning classifiers. We 
applied different strategies to optimize imbalanced class. The 
best model of gradient boosting achieved a significant F1-score 
of 0.82. When testing the model with non-disease genes, we 
predicted 549 candidates, out of which 123 were validated 
indirectly from literature to be related to metabolic diseases. 
The remaining genes’ functions were investigated by gene 
enrichment analysis, revealing their association with diseases 
known to co-occur with metabolic diseases, such as cancer and 
cardiovascular conditions. These results indicated that this 
method contributed to the identification of novel metabolic 
disease-related genes. 
Keywords—metabolic disease, protein-protein interaction 
network, miRNA-target interaction, machine learning, disease 
gene prediction, imbalanced data. 
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I. INTRODUCTION  
Metabolic disease (MD) is an inclusive term used to 
describe a large group of diseases that compromise the normal 
functioning of metabolism. These disorders are distributed 
into two different categories: inherited or acquired during life. 
Inherited MDs, also known as inborn errors of metabolism, 
are diseases that despite being considered as rare individually, 
have a high incidence when considered as a whole. Their 
prevalence is estimated to be about 1 in every 1.000 
individuals [1]. Obesity is an acquired MD with a large 
number of comorbidities and its related diseases include other 
acquired MDs, such as type 2 diabetes, as well as cancer and 
heart disease, which can lead to early death [2]–[4]. Due to the 
increase of MDs on a global scale, there is a demand for 
solutions that can identify genes involved in the emergence of 
these disorders, in the hopes that these can be used in the 
development of new therapeutic strategies. 
One of such strategies consists of combining protein-
protein interactions (PPIs) and miRNA-target interactions 
(MTIs). The majority of proteins work in protein complexes 
and proteins that interact with one another are often found to 
be involved in the same cellular processes, making the study 
of protein-protein interactions (PPIs) more relevant, namely in 
protein function and drug target prediction, as well as in 
disease research [5]–[7]. Due to their regulatory role in 
important cellular functions, such as metabolism and gene 
regulation, the interest in the study of miRNAs involvement 
in disease as biomarkers has recently increased [8], [9]. 
Consequently, the study of integrated networks consisting of 
protein-protein interaction networks (PPINs) and miRNA-
target interaction networks (MTIs) is likely to provide insights 
into MD genes. The choice of these networks is related to the 
commonly accepted principles in bioinformatical protein 
function prediction that neighboring proteins are more likely 
to share functions and that miRNAs that target genes play an 
important role in determining if a gene is disease-related [10]–
[13].  
The use of ML in the biomedical field has been rapidly 
increasing in recent years and examples of its use include 
disease detection and diagnosis, disease prediction and 
prognosis, gene-disease relations, protein function prediction, 
among others [6], [7]. Mordelet et. al. developed an algorithm 
for the identification of disease candidate genes using 
multitask machine learning from positive and unlabeled 
instances [14]. Gene functional similarities were used to train 
machine learning classifiers to predict disease genes [15]. 
miRNA-disease association was predicted by using a boosting 
algorithm (XGBoost) [16]. In a nutshell, ML is a powerful and 
versatile tool that when compared to traditional experimental 
techniques, has the advantage of being significantly faster in 
terms of workflow and production of results.  
However and despite all its advantages, there is a real 
problem occurring in many ML tasks, which is imbalanced 
data [17]–[19]. In biomedical datasets, the positive class is 
commonly much smaller than the negative class and this 
imbalance makes algorithms biased towards the majority 
class, thus affecting their ability to classify and make 
predictions on new data [20]. Given that there is no universal 
solution to this problem, the best approach seems to be trying 
different balancing methods, such as assigning larger penalties 
to wrong predictions, redistributing class weights or 
over/undersampling techniques, and select the one that yields 
the best results for the specific task at hands [20]. 
In this paper, we have proposed an efficient computational 
approach to predict novel MD-related genes by solving a 
critical problem of imbalanced data. This method combined 
PPINs, MTIs and ML classification techniques. We used the 
Synthetic Minority Over-sampling Technique (SMOTE) [21] 
to upsample the minority class in our data and trained a 
gradient boosting classifier (GBC) that achieved an F1-score 
of 0.82 and predicted 549 MD candidate genes. Interestingly, 
there are 123 genes of the 549 candidate ones that were 
inferred to be related to MDs via literature mining. We then 
performed a gene enrichment analysis that showed significant 
associations between the remaining candidate genes with MD 
co-occurring conditions. Our results demonstrated that this 
approach promisingly predicted MD genes. 
II. MATERIALS AND METHODS 
A. Datasets 
Two integrated networks were constructed from two PPI 
databases (DBs). One to extract the features for model training 
and another to make predictions on. To each one of these 
networks, the MTI data was combined, as well as a list of 
known MD genes. 
1) Protein-protein interactions. 
 The Biological General Repository for Interaction 
Databases (BioGRID) [22] was used for training the 
model. BioGRID is a PPI repository, which contains 
literature curated data for several organisms. This DB was 
chosen for the model training not only for the quality of 
its interactions but also by their quantity. BioGRID is a 
very large database, thus providing a good training set.  
Version 3.4.154 for Homo sapiens was used.  
We curated data from the Human Protein Reference 
Database (HPRD) [23], release9_041310 to perform 
predictions. This DB also contains curated PPI 
interactions extracted from literature but just for human 
proteins. In opposition to BioGRID, HPRD is a rather 
small DB but it is a well-known  and reliable human PPI 
database.  
2) miRNA-target interactions.  
The experimentally validated miRNA-target interactions 
database (miRTarBase) [24], was selected because it 
contains the largest amount of solely experimentally 
validated MTIs, collected from relevant literature related 
to miRNA functional studies. The 6.0 release for Homo 
sapiens was downloaded. 
3) Metabolic disease gene list. 
 For the generation of this list, an older version of the MD-
related genes present in the Comparative Toxicogenomics 
Database (CTD) [25] was obtained. This DB aims to 
understand environmental exposures on human health by 
combining information on chemical-gene, chemical-
disease, and disease-gene association. An updated CTD 
list of MD-related genes was also extracted to be used as 
validation for the predicted candidate genes. 
B. Workflow 
The workflow consisted on six major steps, as shown in 
Fig. 1. 
 
Fig.  1. General workflow containing six major steps 
For the data mining step (1), the necessary data for the 
network integration was gathered to obtain two integrated 
networks, one for each PPI DB. Using information from three 
different types of DBs (PPI + MTI + List of known MD 
genes), the two PPI integrated networks were constructed (2). 
The next step is to extract topological features associated with 
each protein present in the integrated network (3). These 
topological features were the features used to train the 
machine learning models on BioGRID (4). Once the best 
predictive model was selected, predictions were made on 
HPRD, to obtain a list of candidate MD genes (5), followed 
by a gene enrichment analysis (6). 
C. Network integration and feature extraction 
For the network integration step, an algorithm adapted 
from [17] was used. A visual guide of the network integration 
is presented in Fig. 2. 
 
Fig.  2. Network integration schematic consisting of three steps.  
The three-step integration was performed for both DBs, 
and the process consisted of first uploading and then 
integrating the PPI and MTI networks, resulting in an 
intermediate network consisting of two types of nodes: normal 
proteins (NPs) and normal proteins targeted by miRNAs 
(NMPs). To this intermediate network, a list of known MD 
genes was added, producing a final network with four types of 
nodes: NPs, NMPs, disease proteins (DPs) and disease 
proteins that are targeted by miRNAs (DMPs). After the 
integration, the radius of each network was computed to find 
out the maximal length of the shortest network. This step was 
performed to avoid including in the training data, features 
which might not be available when forming new predictions, 
like information about very distant nodes. The output files 
from the network integration consist of protein topological 
vectors that served as the features from which the ML 
algorithms were trained. A toy model of both length and 
vectors is presented in Fig. 3. 
 
Fig.  3. Extracted features for machine learning model training 
through different network lengths. 
The topological features consist of four different types of 
nodes showing the number of proteins, which belong to a 
specific type of node that are at a maximal shortest path 
distance from the protein of interest. This maximal distance 
varies between the shortest length, which is one, and the 
maximal network length. In the above example, protein A is 
the protein of interest. For length 1, i.e. the immediate first 
neighbor, the topological vector is as follows: A = (3,1,1,0). 
This means that at a maximal distance 1, protein A interacts 
with 3 NPs, 1 NMP, 1DP and 0 DMPs. If we now consider 
length 2, vector A will be: A = (3,1,1,0,5,3,2,1). This vector 
will increase until the maximal distance of length Max, or the 
maximal length of the network. 
D. Imbalanced data 
SMOTE [21] is an upsampling technique that uses k 
nearest neighbors to create new synthetic minority instances 
based on the real ones. The sampling ratio can go until one, 
meaning that the classes are fully balanced. However, to avoid 
the possible leakage of new data points into the test set and 
consequent overfit and misleading accuracy scores, SMOTE 
should only be used in the training set, after the train/test split. 
E. Machine learning 
For our binary classification problem, a boosting 
algorithm (GBC) was trained. Boosting consists in training an 
ensemble of weak learners in the form of decision trees, with 
the goal of creating a final strong learner. In this iterative 
method, misclassified samples, i.e., samples that are hard to 
classify, gain weight and allow the weak learners to learn from 
them, thus improving the ensemble performance [20]. 
III. RESULTS AND DISCUSSIONS 
Because no wet-lab experimental validation was made on 
the predicted candidate genes, an older version of the known 
MD genes list was used to build the PPINs with the purpose 
of seeing if any of the predicted candidate genes is present in 
the updated MD gene list extracted from CTD, serving as a 
form of validation. The remaining candidate genes not 
validated as MD genes, were the target of a gene enrichment 
analysis, using gene enrichment tool Enrichr [26]. Enrichr is a 
comprehensive resource, containing 184 annotated gene sets 
from 102 gene set libraries. 
All the computational framework was performed using 
Jupyter lab running Python 3.7.2. 
A. Data statistics pre-machine learning.  
After the data curation, the following statistics were 
obtained and are displayed in Tables I and II. 
TABLE  I. Total number of metabolic disease genes extracted from 
the CTD database 
MD genes
# genes 1368 
# genes targeted by miRNAs 1020 
 
TABLE  II. Data extracted from both PPINs and statistics 
including metabolic disease genes and miRNA-target information 
BioGRID HPRD
# interactions 401710 39046
# genes 18233 9455
# MD genes 1159 942
# nonMD genes 17074 8513
# MD genes targeted by miRNAs 13220 816
# nonMD genes targeted by miRNAs 982 7028
 
A tendency for a high frequency of miRNA-target 
interaction towards MD genes seems to be apparent when 
looking at tables I and II, supporting the idea that miRNAs do 
play an important role in determining whether a gene is related 
to disease.  
B. Predicting MD disease genes using gradient boosting 
classifier 
1) Imbalanced data. The BioGRID training data (Table 
II), is quite imbalanced (1159 MD genes to 17074 nonMD 
genes). To approach this problem, a stratified train/test split 
was performed on the training set with a ratio of 80/20 and a 
for loop was  computed to test several balancing SMOTE 
ratios with the GBC, to retrieve the best performing ratio. The 
accuracy scores decreased as the upsampling ratio in the 
training set increased, ranging from the accuracy value of 
0.93 for a balancing ratio of 0.2, to 0.79 for a balancing ratio 
of 1. In the imbalanced test set, the predictor classified the 
majority of instances as belonging the nonMD class, and 
because the MD class is much smaller than the nonMD, the 
accuracy score is high and therefore misleading. As the ratio 
increases, so does the number of correctly predicted MD 
instances but also do the nonMD instances that are predicted 
as MD (false positives), thus decreasing the accuracy score. 
For the final model training, the SMOTE ratio of 1 was used 
and the selected measure to evaluate model performance was 
the F1-Score. The number of training and test set instances 
are shown in Table III. 
TABLE  III. MD and nonMD instances in the training set after 
SMOTE upsampling on the MD class and test set instances 
 MD  nonMD  Total 
Training set 13659 13659 27318
Test set 232 3415 3647
 
2) Feature importance.  To understand which features 
are the most important ones for the classifier to decide to 
which class each sample belongs to, this information was 
extracted (Fig. 4).  
 
Fig.  4. Feature importance for the Gradient Boosting Classifier 
The four most relevant features for the classifier are DMP1 
with an importance of 0.31, DP2 with 0.18, DP1 with 0.15, 
and finally DMP2 with 0.1. All features correspond to disease 
proteins, two of them targeted by miRNAs (DMP1 and 
DMP2). Two of them are the first immediate neighbors 
(DMP1 and DP1), and the other two the second immediate 
neighbors (DP2 and DMP2) of the proteins of interest. These 
results support both the assumptions on which this framework 
was built on. The first one is that neighboring proteins are 
more likely to share functions and the second one that proteins 
that are targeted by miRNAs play an important role in 
determining whether a protein is related to disease. This is 
especially true for the most important feature DMP1: a disease 
protein, targeted by miRNAs that is in the immediate vicinity 
of the protein that will be classified by our model. 
3) Model training and evaluation. A GBC was trained 
using the balanced data with a stratified 10-fold cross-
validation. The model was then tested on the imbalanced test 
set and the evaluation metrics are presented in Table IV. 
TABLE IV. Evaluation metrics obtained for the test set 
Accuracy 0.77 
Precision 0.91 
Recall 0.77 
F1-Score 0.82 
AUC 0.72 
The accuracy scores obtained for the training set (0.79) and 
test set (0.77) were very similar, meaning that the model is 
not overfitting and is a good predictor for new unseen data.  
For the model not to randomly classify the samples as being 
positive, the number of TPs should be high, the number of 
FPs low and the AUC (area under the ROC curve) score 
higher than 0.5. The obtained ROC curve with an AUC of 
0.72 is presented in Fig. 5.  
 
Fig.  5. ROC curve obtained from the GBC.  
To better evaluate the model’ performance, regarding the 
goal of this paper, we looked at the precision (0.91), recall 
(0.77), and their harmonic mean, the FI-score (0.82).  
C. Predictions 
To test the performance of the model, we used HRPD data 
for predicting new candidate genes (Fig. 6). 
 
Fig.  6. MD and nonMD predicted genes for the HPRD DB 
 HPRD is also highly imbalanced, 942 MD to 8,513 
nonMD. The classifier correctly predicted less than half the 
actual MD instances (403) and in addition to the imbalance, 
these results can be also explained by the difference between 
both network properties. We predicted 1,442 new candidate 
genes and to reduce this number, the median of the obtained 
prediction probabilities was computed (0.67) and a cut-off 
was performed, reducing the initial list of candidate genes 
from 1,442 to 549.  
D. Validation 
The CTD list used for the PPIN integration has 1,368 MD 
genes and the updated CTD list used for validation 3,183. The 
final list of 549 predicted candidate genes was compared to 
the updated CTD list of known MD genes to look for 
overlaps. A total of 123 predicted candidate genes was 
confirmed as being a known MD gene, supporting the idea 
that the proposed framework can help improve the 
identification of novel MD genes. The hypergeometric p-
value of the validated 123 genes is  2.6645e-15, showing the 
statistical significance of our results. The remaining 426 
candidate genes were subjected to an enrichment analysis 
performed on the Enrichr [26] tool. The obtained results show 
the associations between the candidate genes and diseases 
obtained in the Online Mendelian Inheritance in Man 
(OMIM) [27] DB (Fig. 7  - A) and PPINs connecting disease 
genes from OMIM (Fig 7 - B). 
 
Fig.  7. Gene enrichment analysis performed using Enrichr, 
showing the results obtained for the OMIM DB.  
This analysis revealed the association of these candidate 
genes with autoimmune diseases like systemic lupus 
erythematosus, cardiovascular problems, such as myocardial 
infarction and coronary heart disease, as well as leukemia and 
colorectal cancers. Given the comorbidity that these diseases 
have with MDs, these genes seem to be suitable MD candidate 
genes.  
IV. CONCLUSION 
In this paper, we presented a pipeline that can contribute 
to the prediction of disease candidate genes by combining 
PPIN properties, MTIs, data balancing techniques and ML 
classification. From the predicted candidate genes, 123 genes 
were validated as MD genes and the remaining ones were 
associated with diseases known to co-occur with MDs, 
therefore reinforcing the importance of PPINs and miRNAs in 
novel disease candidate genes prediction, as well as the 
importance of dealing with the imbalanced data problem in 
ML. These achieved results showed the potential in the 
identification of novel disease candidate genes. 
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